Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Leases (2022 - 2025)

Corvus Pharmaceuticals has reported Current Leases over the past 4 years, most recently at $379000.0 for Q3 2025.

  • Quarterly results put Current Leases at $379000.0 for Q3 2025, up 7.06% from a year ago — trailing twelve months through Sep 2025 was $379000.0 (up 7.06% YoY), and the annual figure for FY2024 was $185000.0, down 86.54%.
  • Current Leases for Q3 2025 was $379000.0 at Corvus Pharmaceuticals, up from $355000.0 in the prior quarter.
  • Over the last five years, Current Leases for CRVS hit a ceiling of $1.4 million in Q4 2023 and a floor of $185000.0 in Q4 2024.
  • Median Current Leases over the past 4 years was $1.1 million (2022), compared with a mean of $882533.3.
  • Biggest five-year swings in Current Leases: grew 15.87% in 2023 and later tumbled 86.54% in 2024.
  • Corvus Pharmaceuticals' Current Leases stood at $1.2 million in 2022, then increased by 11.89% to $1.4 million in 2023, then tumbled by 86.54% to $185000.0 in 2024, then surged by 104.86% to $379000.0 in 2025.
  • The last three reported values for Current Leases were $379000.0 (Q3 2025), $355000.0 (Q2 2025), and $319000.0 (Q1 2025) per Business Quant data.